# A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

> **NCT00281632** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 35 (actual)

## Conditions studied

- Peritoneal Cancer
- Ovarian Cancer
- Neoplasms, Ovarian
- Fallopian Tube Cancer

## Interventions

- **DRUG:** GW786034

## Key facts

- **NCT ID:** NCT00281632
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-04
- **Final completion:** 2010-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281632, "A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00281632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*